According to Zacks, “Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company’s lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. “
Shares of Can-Fite BioPharma stock traded down $0.00 during trading hours on Thursday, hitting $0.97. The company’s stock had a trading volume of 156,354 shares, compared to its average volume of 270,389. Can-Fite BioPharma has a 12-month low of $0.78 and a 12-month high of $2.62. The company has a market capitalization of $26.51 million, a price-to-earnings ratio of -1.41 and a beta of 1.83.
An institutional investor recently raised its position in Can-Fite BioPharma stock. Morgan Stanley increased its stake in shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) by 351.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,873 shares of the biotechnology company’s stock after buying an additional 62,197 shares during the period. Morgan Stanley owned 0.46% of Can-Fite BioPharma worth $197,000 at the end of the most recent quarter. Institutional investors own 5.40% of the company’s stock.
About Can-Fite BioPharma (Get Rating)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
- Get a free copy of the StockNews.com research report on Can-Fite BioPharma (CANF)
- The Institutions Are Rotating Into Olli’s Bargain Outlet
- Inflation, An Economic Winter Is Approaching
- Microcap Oil-Dri Corporation Is A Buy For Income Investors
- Would Netflix acquiring Roku be a positive for the stock?
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.